Parkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings. Pathological aggregation of α-synuclein and the consequent death of dopaminergic neurons are the primary drivers of PD pathogenesis. While siRNA-mediated knockdown of α-synuclein can offer some protection to dopaminergic neurons, its clinical utility is hampered by low cellular uptake, off-target effects, and transient activity. These drawbacks underscore the urgent need for novel strategies that can efficiently and specifically degrade α-synuclein to delay or even halt PD progression.
Our prior work identified tat-βsyn-deg (PDR-001), a three-segment peptide that selectively targets α-synuclein. When packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus, this peptide effectively reduces α-synuclein within the target region. Pre-clinical studies in both human-α-synuclein-expressing mice and non-human primate models of PD have demonstrated robust α-synuclein clearance and marked improvements in motor deficits (see Research Foundation).
The present project will advance PDR-001 into first-in-human studies to evaluate safety and explore preliminary efficacy. Unlike conventional symptomatic therapies, this approach targets the root cause of PD, setting the stage for disease-modifying treatment. Successful translation would establish a new therapeutic paradigm capable of slowing or preventing PD progression.

Start Date20 Oct 2025

Sponsor / Collaborator

Ruijin Hospital

NCT05201066

/ Active, not recruitingPhase 2

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

Start Date13 Feb 2023

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NL-OMON51829

/ RecruitingNot Applicable

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments - CPDR001X2X01B

Start Date30 Aug 2022

Sponsor / Collaborator

Novartis AG

100 Clinical Results associated with Spartalizumab

100 Translational Medicine associated with Spartalizumab

100 Patents (Medical) associated with Spartalizumab

Literatures (Medical) associated with Spartalizumab

01 Mar 2026·EUROPEAN JOURNAL OF CANCER

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study

Article

Author: Corbinais, Stéphane ; Piessen, Guillaume ; Guilloit, Jean-Marc ; Bouche, Olivier ; Parzy, Aurélie ; Desgrippes, Romain ; Samalin, Emmanuelle ; Le Sourd, Samuel ; Lequesne, Justine ; Tougeron, David ; Guimbaud, Rosine ; Leconte, Alexandra ; Hiret, Sandrine ; Dahan, Laetitia ; Galais, Marie-Pierre ; Dos Santos, Mélanie ; Soularue, Emilie ; Borg, Christophe ; Pernot, Simon ; Varatharajah, Sharmini ; Brachet, Pierre-Emmanuel ; Dorbeau, Marine ; Clarisse, Bénédicte

PURPOSE:

Perioperative chemotherapy with FLOT is a standard of care for patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. This trial evaluated the anti-PD-1 monoclonal antibody spartalizumab combined with FLOT as perioperative treatment for resectable patients.

PATIENTS AND METHODS:

GASPAR is a multicenter, single-arm, Simon two-stage phase 2 trial. Patients with untreated localized gastric or GEJ adenocarcinoma considered resectable (≥ cT2 or cN+) received 4 pre- and post-operative cycles of FLOT and 2 pre- and post-operative cycles of spartalizumab. The main endpoint was the rate of pathological complete regression (pCR) according to the Becker criteria, requiring 67 patients (H0/H1 =10/23 %, α=5 %, β=20 %).

RESULTS:

Overall, 68 patients were included: men (78 %), median age 63 years [range 31-79], cT3 51 %, GEJ 60 %, cN+ 58 %. Treatment was started in 67 patients. Delayed FLOT administration for toxicity and dose reduction concerned 14 (21 %) and 28 (42 %) patients, respectively. Surgery was R0 in 62 (95 %) of the patients operated on. Among 64 patients assessable for efficacy, pCR was observed in 20 patients (31 %), and major pathological response in 12 patients (19 %), meaning a major response rate of 50 %. Five patients developed grade 3 immune-mediated adverse events. One death related to pneumocystis occurred. Severe post-surgery complications occurred in 15 patients (23 %). After a median follow-up of 30 months [range 4-42], OS and DFS at 2 years were 86 % [77.8-94.9] and 77.5 % [68.1-88.2], respectively.

CONCLUSIONS:

Spartalizumab combined with FLOT shows high efficacy as perioperative treatment in patients with resectable gastric cancer, and an acceptable safety profile.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT04736485.

03 Oct 2025·MEDICINE

Global safety profile of PD-1/PD-L1 inhibitors in hepatic autoimmune disorders: A global disproportionality analysis

Article

Author: Kong, Jaehyun ; Hwang, Jiyoung ; Yon, Dong Keon ; Cho, Jaehyeong ; Park, Jaeyu ; Oh, Jeongseon ; Kim, Tae Hyeong ; Kim, Tae Hyeon

The increasing use of programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors in cancer therapy has raised concerns regarding immune-related adverse events. However, global pharmacovigilance studies on autoimmune diseases remain scarce. This study aimed to evaluate the signal detection between PD-1/PD-L1 inhibitors and hepatic autoimmune disorders. A global pharmacovigilance study was conducted using data from individual case safety reports. The analysis centered on PD-1/PD-L1 inhibitors, classified by Anatomical Therapeutic Chemical codes (e.g., atezolizumab, avelumab, budigalimab, cemiplimab, dostarlimab, durvalumab, nivolumab, pembrolizumab, sintilimab, spartalizumab, and tislelizumab). Hepatic autoimmune disorders were defined based on MedDRA Version 26.0 (Maintenance and Support Services Organization, McLean). Disproportionality analyses were performed using reporting odds ratios with 95% confidence intervals and information components (ICs), with IC 0.25 , to evaluate potential signal detection. A total of 1401 reports of hepatic autoimmune disorders associated with PD-1/PD-L1 inhibitors were identified. Nivolumab (59.89%) and pembrolizumab (27.62%) accounted for the highest reports. Notably, nivolumab (reporting odds ratio, 117.52 [95% confidence interval, 109.52–126.10]; IC, 6.67 [IC 0.25 , 6.60]) and pembrolizumab (55.69 [50.31–61.64]; 5.65 [5.55]) showed the notable reporting signals, followed by cemiplimab, atezolizumab, durvalumab, avelumab, sintilimab, and tislelizumab. Subgroup analysis showed a stronger signal for hepatic autoimmune disorders in males than in females treated with PD-1/PD-L1 inhibitors. Additionally, the mean time to onset was 22.90 days (standard deviation: 81.66), although some reports presented with substantially delayed onset. Most PD-1/PD-L1 inhibitors showed pharmacovigilance signals for hepatic autoimmune disorders, particularly nivolumab and pembrolizumab. Although our findings do not permit causal inference, these findings underscore the necessity for sustained hepatic monitoring, risk stratification, and appropriate therapeutic management.

01 Oct 2025·ESMO Open

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

Article

Author: Sanfeliu, E ; Amillano, K ; González, B ; Martín-Liberal, J ; Paz-Ares, L ; Garralda, E ; Ciruelos, E ; González, X ; Aguirre, Á ; Castillo, O ; Pascual, T ; Vivancos, A ; Saura, C ; Cervantes, A ; Conte, B ; Villacampa, G ; Victoria, I ; Hierro, C ; Galván, P ; Mulero-Sánchez, A ; Seguí, E ; Gavilá, J ; Ferrero-Cafiero, J M ; Brasó-Maristany, F ; Walbaum, B ; Prat, A ; Indacochea, A ; Blasco, P ; Salvador, F ; Racca, F ; Cejalvo, J M ; Pardo, F ; Mesía, R ; Arance, A ; Juan, M ; Tabernero, J ; Sirenko, V ; Izarzugaza, Y ; López-González, A ; Felip, E

BACKGROUND:

Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid tumors, yet responses vary across cancer types, highlighting the need for reliable pan-cancer biomarkers. Prior retrospective studies identified PD1 mRNA as a promising predictor of anti-PD1 response, but prospective validation was lacking.

PATIENTS AND METHODS:

The SOLTI-1904 ACROPOLI trial was a non-randomized, open-label, multicenter phase II study designed to evaluate the efficacy of anti-PD1 monotherapy in patients with advanced solid tumors and high PD1 mRNA expression (cohort 1). An exploratory cohort also enrolled PD1-low tumors from cancer types with known ICI sensitivity (cohort 2). Between April 2021 and March 2022, 1003 patients across 33 cancer types were prescreened; 10.6% were classified as PD1-high. A total of 56 PD1-high and 15 PD1-low cases were enrolled to receive spartalizumab (400 mg intravenously every 4 weeks). The primary endpoint was objective response rate (ORR) in PD1-high tumors. Cohorts 1 and 2 were closed early due to discontinuation of spartalizumab development, before reaching full accrual.

RESULTS:

In the PD1-cohort, which included heavily pretreated tumors (median two prior lines) across 19 histologies, the ORR was 17.9% (95% confidence interval 7.8% to 27.9%). Among patients with tissue samples collected within 12 months of treatment, the ORR increased to 33.3%. The clinical benefit rate (partial response or stable disease ≥24 weeks) was 30.4%. Responses occurred in cancers typically resistant to ICIs, including pancreatic and microsatellite-stable colorectal cancers. No new safety signals were identified. Programmed death-ligand 1 expression by immunohistochemistry was significantly associated with response, whereas exploratory analyses identified additional potential biomarkers, including B cell gene signatures and tumor proliferation markers.

CONCLUSIONS:

PD1 mRNA may help identify immunogenic tumors across cancer types. However, the trial's early closure and exploratory nature warrant further validation. A composite biomarker strategy integrating immune and tumor-intrinsic features may improve patient selection for ICIs.

News (Medical) associated with Spartalizumab

25 Apr 2023

·www.fiercebiotech.com

Novartis prunes assets, axing 10% of pipeline programs to narrow R&D focus

The number of projects in Novartis’ pipeline fell from 150 to 134. Novartis has undertaken an old-fashioned decimation of its pipeline. The Swiss drugmaker has decided to dump or out-license 10% of its R&D projects to narrow its sights on five core therapeutic areas and focus investment on its most promising programs within those spaces. In recent quarters, Novartis has decided to make five therapeutic areas—cardiovascular, hematology, solid tumors, immunology and neuroscience—and a small clutch of technology platforms the focus of its R&D activities. More recently, disclosures about partnered programs that Novartis is dumping gave hints that an overhaul was underway. Now, Novartis has shared a full look at its slimmed-down pipeline. “We reduced our pipeline size by about 10%. And that's primarily as we prune assets that are outside of those five core therapeutic areas, or in the sixth area we call TAX which incubate certain therapeutic areas we're interested in,” Novartis CEO Vas Narasimhan, M.D., said on an early morning call with the media. “So we've taken the principal decision that if it doesn't fit within that framework, we are either going to stop the programs or divest them.” Expanding on the decision in a later call with analysts, Narasimhan explained that part of the pipeline “cleanup” had been the result of benchmarking Novartis’ R&D against its fellow Big Pharmas. “We had more projects than our peers, which led us to have less investment per project versus the peer set,” the CEO explained. “We think that's important because in having strong investment in the early stage pre-clinically or in early clinical can also help us go faster, go broader into more lines of therapy, more indications.” As a result of the changes, the number of projects in Novartis’ pipeline has fallen from 150 to 134. Solid tumors, an ongoing area of focus, took the biggest hit, with the number of active projects falling from 42 to 32 between the two updates. Addressing the significant reduction in early-stage cancer assets, Narasimhan told analysts that Novartis had removed candidates with targets that “are no longer priority tumors for the company.” Below, we provide an overview of the programs that Novartis dropped from its pipeline in its quarterly pipeline update. But before getting to that, there is one candidate clinging on that is nonetheless worth discussing. In the fourth quarter, Novartis listed six studies involving spartalizumab, an anti-PD-1 checkpoint inhibitor that failed a phase 3 melanoma trial in 2020. Today, only one study remains. Phase 2 ADPT06: A cognitive impairment candidate that Novartis tested in a phase 2 platform clinical trial of various anti-inflammatory agents. The mechanism of action is unknown. Novartis tested canakinumab, sold in other indications as Ilaris, in the same trial of patients with mild cognitive impairment due to Alzheimer's disease. HSY244: An atrial fibrillation candidate that Novartis took into phase 2 in 2020. Novartis “prematurely ended” the study, per the European database, but ClinicalTrials.gov still lists it as recruiting patients. Ensovibep: The COVID-19 antiviral that Novartis bought at the start of last year for 150 million Swiss francs ($168 million). Within months, Novartis’ plan to bring the molecule to market unraveled as the FDA requested phase 3 data. Novartis licensed the asset from Molecular Partners. LKA651: A MorphoSys-partnered EPO inhibitor that Novartis studied in diabetic macular edema. Novartis completed a phase 2 clinical trial of the drug candidate last summer. Phase 1 FIA586: The final domino to fall in Novartis’ exit from nonalcoholic steatohepatitis (NASH). The Swiss drugmaker wrapped up an early-phase trial of the candidate in mild and moderate hepatic impairment last summer. MHS552: An autoimmune disease candidate that Novartis was studying in a phase 1 lupus trial when it decided to pull the plug. The company filed to test the molecule in type 1 diabetes but withdrew the study before enrolling any patients. ADPT03: A BCL11A program targeting sickle cell disease. Intellia disclosed that Novartis had stopped work on an ex vivo, CRISPR-edited cell therapy designed to reduce the activity of BCL11A earlier this year. JEZ567: A anti-CD123 CAR-T cell therapy that Novartis was developing in acute myeloid leukemia. MAK683: An inhibitor of embryonic ectoderm development protein that Novartis has studied in people with diffuse large B-cell lymphoma since 2016. WVT078: A BCMAxCD3 bispecific antibody that Novartis studied in multiple myeloma. The presence of many other BCMA candidates at other companies makes WVT078 a poor fit for Novartis’ focus on “high value medicines with transformative potential for patients.”

Phase 2Cell TherapyPhase 1ImmunotherapyClinical Result

16 Nov 2022

·www.fiercebiotech.com

Novartis halts phase 1 cancer trial of CD73 antagonist over efficacy, but combo studies continue

A failed study of Novartis' CD73 antagonist enrolled 127 participants with advanced malignancies who received NZV930 either as a monotherapy or in combination. Novartis has halted a phase 1 trial of its CD73 antagonist due to a low likelihood of efficacy, although the Big Pharma will continue to explore the therapy’s potential as part of a combo regimen. The trial of NZV930 was “terminated early because data review showed low likelihood of efficacy in the patients recruited in that clinical setting,” a Novartis spokesperson confirmed to Fierce Biotech. The decision was not safety-related, they added. The study, which began in July 2018, enrolled 127 participants with advanced malignancies who received NZV930 either as a monotherapy or in combination with Novartis’ checkpoint inhibitor spartalizumab or its adenosine A2a receptor antagonist NIR178, according to ClinicalTrials.gov. Novartis will continue to evaluate whether NZV930 is effective when used in combination with other investigational agents, the spokesperson told Fierce. They pointed to an ongoing phase 1 trial of KAZ954 in advanced solid tumors that includes a cohort receiving the investigational therapy in combination with NZV930. The aim of CD73 antagonists is to block the CD73 enzyme from producing adenosine, which can suppress the body’s immune response to cancer. Novartis is not alone in exploring this mechanism: I-Mab’s uliledlimab showed promise alongside Junshi Bioscience’s PD-1 inhibitor toripalimab in initial phase 2 data, while AstraZeneca’s CD73 antagonist oleclumab is in phase 2 trials for pancreatic cancer and phase 3 trials for lung cancer, including in combination with Imfinzi.

Phase 2Phase 1Clinical Trial FailurePhase 3Clinical Trial Termination

11 Oct 2022

·www.prnewswire.com

Esophageal Cancer Clinical Trial Pipeline Insights Featuring 80+ Companies | DelveInsight

The prevalence of esophageal cancer has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of cancer and the increase in research & development. The Companies developing the potential therapies in the last stage of development include Celgene,Jiangsu HengRui Medicine Co., Seagen, and several others. LAS VEGAS, Oct. 11, 2022 /PRNewswire/ -- DelveInsight's ' Esophageal Cancer Pipeline Insight – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline esophageal cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the esophageal cancer pipeline domain. Key Takeaways from the Esophageal Cancer Pipeline Report DelveInsight's esophageal cancer pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for esophageal cancer treatment. Leading esophageal cancer companies such as Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others are evaluating new drugs for esophageal cancer treatment. Key esophageal cancer pipeline therapies in various stages of development include Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, AP 203, QEQ278, JAB-3312, DKN-01, AN0025, HR 070803,Oraxol, Sunitinib malate, Tiragolumab, iNeo Vac P01, Amivantamab, CA-4948, M1231, APX005M, DC-CIK, Margetuximab, Temozolomide, and others. In September 2022, Daiichi Sankyo and Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase I/II trial of DS-7300, continued to show promising durable tumor response in patients with several types of heavily pretreated cancers including lung, prostate or esophageal cancer.A response rate of 32% (95% CI: 24-41) was observed with 38 responses (33 confirmed; 28%; 95% CI: 20-37) in 118 patients with various solid tumors including small cell lung cancer (SCLC), squamous non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC) or endometrial cancer receiving doses of DS-7300 ranging from 4.8 mg/kg to 16.0 mg/kg. In September 2022, Integral Molecular, has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) MAbs. Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid tumors including gastric, lung, pancreatic and esophageal cancers. CARTEXELL will be solely responsible for all research, development, and commercial activities. In August 2022, BeiGene announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab in combination with chemotherapy as first-line treatment in patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). In May 2022, Shanghai Junshi Biosciences Co., Ltd, announced that the China National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). The sNDA was accepted by the NMPA in July 2021. This is the fifth indication approved for toripalimab in China and will benefit Chinese patients with advanced ESCC. In May 2022, Bristol Myers Squibb, announced that the U.S. Food and Drug Administration (FDA) has approved both Opdivo (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status. The approvals are based on the Phase III CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase III trial of immunotherapy in first-line ESCC. In January 2022, Lyell Immunopharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK. Request a sample and discover the recent advances in esophageal cancer treatment @ Esophageal Cancer Pipeline Report The esophageal cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage esophageal cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the esophageal cancer pipeline landscape. Esophageal Cancer Overview Esophageal cancer grows in the esophagus, the tube that connects the throat to the stomach. Tumors develop in the mucosa, the inner lining of the esophagus. Esophageal cancer is classified into two types, each with its own set of risk factors: Adenocarcinoma -Adenocarcinomas are cancers that begin in gland cells at the bottom of the esophagus. This is the most common type of esophageal cancer. It usually happens near the stomach. The exact esophageal cancer causes are not known. Most esophageal cancer symptoms do not appear until cancer has progressed to an advanced stage, when it may be challenging to treat. Other, more common conditions can cause esophageal cancer symptoms. The most common esophageal cancer symptom is difficulty swallowing, particularly a sensation of food stuck in the chest. There are several tests used for esophageal cancer diagnosis. The most common include endoscopy with biopsy and endoscopic ultrasonography. Find out more about esophageal cancer drugs in development @ New Treatment for Esophageal Cancer A snapshot of the Esophageal Cancer Pipeline Drugs mentioned in the report: Learn more about the emerging esophageal cancer pipeline therapies @ Esophageal Cancer Clinical Trials Esophageal Cancer Therapeutics Assessment The esophageal cancer pipeline report proffers an integral view of esophageal cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Esophageal Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Prostaglandin E EP4 receptor antagonists, ERBB 2 receptor antagonists, Phosphorylation inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants, CD40 antigen stimulants, Immunostimulants, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Epidermal growth factor receptor antagonists. Key Esophageal Cancer Companies: Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL and others Key Esophageal Cancer Pipeline Therapies: Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, AP 203, QEQ278, JAB-3312, DKN-01, AN0025, HR 070803,Oraxol, Sunitinib malate, Tiragolumab, iNeo Vac P01, Amivantamab, CA-4948, M1231, APX005M, DC-CIK, Margetuximab, Temozolomide and others. Dive deep into rich insights for esophageal cancer drugs, visit @ Chemo Drugs for Esophageal Cancer Treatment Table of Contents For further information on the esophageal cancer pipeline therapeutics, reach out @ New Drug for Esophageal Cancer Treatment Related Reports Esophageal Cancer Market Esophageal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal cancer companies including Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, among others. Esophageal Cancer Epidemiology Forecast Esophageal Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Esophageal Squamous Cell Carcinoma Pipeline Esophageal Squamous Cell Carcinoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal squamous cell carcinoma companies, including BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others. Esophageal Squamous Carcinoma Market Esophageal Squamous Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key esophageal squamous carcinoma companies, including BeiGene, AstraZeneca, Ipsen, Shire, Sanofi, Seagen, among others. Esophageal Squamous Cell Carcinoma Epidemiology Esophageal Squamous Cell Carcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted esophageal squamous cell carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Other Trending Reports Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Gene TherapyAntibodyBiosimilarOligonucleotideCell Therapy

100 Deals associated with Spartalizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D11605	Spartalizumab	-	DB14892

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	17 Feb 2017
Melanoma	Phase 3	Japan	Novartis Pharmaceuticals Corp.	17 Feb 2017
Melanoma	Phase 3	Canada	Novartis Pharmaceuticals Corp.	17 Feb 2017
Melanoma	Phase 3	Germany	Novartis Pharmaceuticals Corp.	17 Feb 2017
Melanoma	Phase 3	Italy	Novartis Pharmaceuticals Corp.	17 Feb 2017
Melanoma	Phase 3	Netherlands	Novartis Pharmaceuticals Corp.	17 Feb 2017
Melanoma	Phase 3	Spain	Novartis Pharmaceuticals Corp.	17 Feb 2017
Melanoma	Phase 3	Switzerland	Novartis Pharmaceuticals Corp.	17 Feb 2017
Unresectable Melanoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	17 Feb 2017
Unresectable Melanoma	Phase 3	Japan	Novartis Pharmaceuticals Corp.	17 Feb 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05210413 (SPARTO, ASCO2026)	Phase 1	-	41	Spartalizumab at 2 mg/kgPazopanib 225 mg/m²/d/kg + Spartalizumab at 2 mg/kgPazopanib 225 mg/m²/d	czotcyjvwp(qmcstaskhq) = one patient experienced liver enzymes increase grade > 3 at DL2 zosqmqrcee (sxjumikqxk ) View more	Positive	29 May 2026
NCT05210413 (SPARTO, ASCO2026)	Phase 1	-	41	Spartalizumab at 3 mg/kgPazopanib 225 mg/m²/d/kg + Spartalizumab at 3 mg/kgPazopanib 225 mg/m²/d		Positive	29 May 2026
NCT04028245 (SPARC-1, AACR2026)	Phase 1	Renal Cell Carcinoma Neoadjuvant	14	Spartalizumab (αPD-1)Canakinumab (αIL-1β) + Spartalizumab (αPD-1)Canakinumab (αIL-1β))	zwkpkihohr(afudmkxbdp) = qxfpiizovj kcbwxrrpuv (zxfjxomcir )	Positive	18 Apr 2026
NCT04736485 (GASPAR, CTgov)	Phase 2	Stomach Cancer	67	Docétaxel+Leucovorin+Spartalizumab+Oxaliplatine+Fluorouracile	vkkupedqql = cwxfgmjnyl chxfrlbltb (ucpqkczjmz, gfvyzzynir - jbjtysgzpf) View more	-	14 Apr 2026
NCT04736485 (GASPAR, Pubmed \| Eur J Cancer)	Phase 2	Stomach Cancer	64	Spartalizumab + FLOT	dscqlumdou(oapscbutok) = mvsbfsajeb zpokggpodt (uvddryeciw ) View more	Positive	01 Mar 2026
NCT04581343 (PanCAN-SR1, CTgov)	Phase 1	Metastatic Pancreatic Cancer \| Metastatic Pancreatic Ductal Adenocarcinoma	10	Canakinumab	stomilziol = zldfrktqjf vjllvmyrrs (wcuyorqyxy, affqolkfll - fiszjkxuso) View more	-	08 Apr 2025
NCT03668431 (NEWS) Manual	Phase 2	BRAF V600E mutant Colorectal Cancer BRAF V600E	37	Dabrafenib + Trametinib + Spartalizumab	dpeihedptk(crpmfgwxir) = fiiqjpohwy fiowfjyeus (zezfvklwyg ) View more	Positive	01 Mar 2025
NCT04310397 (CTgov)	Phase 2	BRAF V600K Mutation-Positive Melanoma \| Melanoma, Cutaneous Malignant	4	Dabrafenib+trametinib+Spartalizumab	iddthbizyo(erslcxyniv) = yetvqgvykt oinkwqbbhj (mjucacccuh, tuxcpgntnn - eoiebshcrm) View more	-	30 Oct 2024
NCT03064854 (not available, Pubmed \| BMC Cancer) Manual	Phase 1	metastatic non-small cell lung cancer First line	-	Spartalizumab 300 mg Q3W + Gemcitabine/Cisplatin	dtspnqbvrt(hfqbtqwtyw) = pjsqdihfab omzimdlvft (dyewalhgfe ) View more	Positive	24 Oct 2024
NCT03064854 (not available, Pubmed \| BMC Cancer) Manual	Phase 1	metastatic non-small cell lung cancer First line	-	Spartalizumab 300 mg Q3W + Pemetrexed/Cisplatin	dtspnqbvrt(hfqbtqwtyw) = aakbnyodpe omzimdlvft (dyewalhgfe ) View more	Positive	24 Oct 2024
NCT04544111 (ESMO2024) Manual	Phase 2	Refractory Thyroid Gland Carcinoma	19	TrametinibPDR001	uzrjvjdlqv(awhbuwscle) = jiyofqldzf mnnfgiawsd (wlpomiaost ) View more	Positive	16 Sep 2024
NCT04544111 (ESMO2024) Manual	Phase 2	Refractory Thyroid Gland Carcinoma	19	dabrafenib+PDR001 (BRAFV600E- tumors after progression on BRAF-directed therapy)	uzrjvjdlqv(awhbuwscle) = mnniyeisdr mnnfgiawsd (wlpomiaost ) View more	Positive	16 Sep 2024
NCT04323436 (CTgov)	Phase 2	Non-Small Cell Lung Cancer	31	Spartalizumab+Capmatinib (Run-in Part: Capmatinib 400 mg BID + Spartalizumab 400 mg Q4W)	osvcegbmok = jlqmifsxfj zxsubkiwcd (nusybyvhet, tgspcgehft - xcsftngepm) View more	-	06 Feb 2024
NCT04323436 (CTgov)	Phase 2	Non-Small Cell Lung Cancer	31	Spartalizumab+Capmatinib (Run-in Part: Capmatinib 400mg BID + Spartalizumab 400mg Q4W (Prior Discontinuing Spartalizumab))	gbmnpbhgex(xlorqsctfa) = efemoqofqv lkbuysirui (ulaojkaqjh, avehfpehas - ifspcycojm) View more	-	06 Feb 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis